Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imatinib mesylate.

Danial E Baker1

  • 1College of Pharmacy, Washington State University, Spokane, WA, USA.

Reviews in Gastroenterological Disorders
|July 19, 2002
PubMed
Summary
This summary is machine-generated.

Imatinib is a molecularly targeted drug that selectively eliminates cancer cells. It is approved for treating specific gastrointestinal stromal tumors and Philadelphia chromosome-positive chronic myeloid leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Audit and Feedback of Targeted Antimicrobials Use at a Tertiary Care Hospital in the United Arab Emirates.

Antibiotics (Basel, Switzerland)·2025
Same author

Sulopenem Etzadroxil/Probenecid.

Hospital pharmacy·2025
Same author

Axatilimab.

Hospital pharmacy·2025
Same author

Respiratory Syncytial Virus Vaccine (mRNA).

Hospital pharmacy·2024
Same author

Resmetirom.

Hospital pharmacy·2024
Same author

Cefepime/Enmetazobactam.

Hospital pharmacy·2024
Same journal

Prevalence and risk factors of fecal incontinence in community-dwelling men.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea - novel transdermal patch vaccine to prevent travelers' diarrhea.

Reviews in gastroenterological disorders·2010
Same journal

Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea--cryptosporidial diarrhea in patients with AIDS: impressive results with Rifaximin.

Reviews in gastroenterological disorders·2009
Same journal

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Reviews in gastroenterological disorders·2009
Same journal

Antimicrobial resistance and eradication strategies for Helicobacter pylori.

Reviews in gastroenterological disorders·2009
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Imatinib represents a novel class of molecularly targeted cancer therapies.
  • This drug demonstrates selective cytotoxicity towards cancer cells, sparing healthy tissues.
  • Its development is based on the principle of targeting specific molecular pathways driving cancer growth.

Purpose of the Study:

  • To outline the therapeutic indications for imatinib mesylate.
  • To highlight its mechanism of action in targeting cancer cells.

Main Methods:

  • Review of clinical data and drug development principles.
  • Identification of specific patient populations and cancer types responsive to imatinib.

Main Results:

Related Experiment Videos

  • Imatinib mesylate is indicated for Kit (CD117)-positive unresectable or metastatic gastrointestinal stromal tumors.
  • It is also indicated for Philadelphia chromosome-positive chronic myeloid leukemia in various phases, including post-interferon-alfa failure.

Conclusions:

  • Imatinib mesylate is a key therapeutic agent in molecularly targeted cancer treatment.
  • Its efficacy is demonstrated in specific hematologic and solid tumors characterized by distinct molecular markers.